The invention relates to new arylglycinamide derivatives of general formula I ##STR1## and the pharmaceutically acceptable salts thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and Ar have the meanings given in the specification, and the preparation and use thereof. The new compounds are valuable neurokin (tachykinin) antagonists.
RELATED APPLICATIONS
This application is a continuation, under 37 FR 1.53(b), of prior application Ser. No. 08/947,785, filed Oct. 9, 1997, now U.S. Pat. No. 5,861,509, which is a continuation of prior application Ser. No. 08/688,478, filed Jul. 30, 1996, now U.S. Pat. No. 5,710,155, which is a continuation of prior application Ser. No. 08/473,470, filed Jun. 7, 1995, now abandoned.
The invention relates to new arylglycinamide derivatives of general formula I ##STR1## and the pharmaceutically acceptable salts thereof, wherein R.sup.1 and R.sup.2 together with the N to which they are bound form a ring of the formula ##STR2## wherein is 2 or 3 and X denotes oxygen, N(CH.sub.2).sub.n R.sup.6 or CR.sup.7 R.sup.8, and R.sup.3.sub.4 R.sup.5 R.sup.6 R.sup.7, R.sup.8, Ar and n have the meanings given in the specification, and the preparation and use thereof. The new compounds are valuable neurokinin (tachykinin)-antagonists.
The invention relates to new arylglycinamide derivatives of general formula I ##STR1## and the pharmaceutically acceptable salts thereof, wherein R.sup.1 and R.sup.2 together with the N to which they are bound form a ring of the formula ##STR2## wherein p is 2 or 3 and X denotes oxygen, N(CH.sub.2).sub.n R.sup.6 or CR.sup.7 R.sup.8, and R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, Ar and n have the meanings given in the specification, and the preparation and use thereof. The new compounds are valuable neurokinin (tachykinin)-antagonists.
